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Sera from 1483 female subjects in England aged 10–29 years were tested. The age-standardised seroprevalence was 10.7% (95%
confidence intervals 9.0–12.3) for human papillomavirus (HPV) 6, 2.7% (1.8–3.6) for HPV 11, 11.9% (10.2–13.6) for HPV 16, 4.7%
(3.5–5.8) for HPV 18, and 20.7% (18.6–22.7) for any of the four types.
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Infection with human papillomavirus (HPV) types identified as
‘high-risk’ is a pre-requisite for developing cervical cancer (Munoz
et al, 2003). HPV types 16 and 18 are associated with 70% of
cervical cancers worldwide (Munoz et al, 2003), while HPV types 6
and 11, although not ‘high-risk’, are associated with over 90% of
cases of anogenital warts (von Krogh et al, 2001). Two prophylactic
vaccines against HPV (a bivalent vaccine against types 16 and 18,
and a quadrivalent vaccine that also includes types 6 and 11) have
been shown in clinical trials to reduce persistent HPV infection
and associated disease by over 90% in up to 5 years of follow-up
(Harper et al, 2004; Villa et al, 2006).
Epidemiological knowledge of HPV infection in the UK relies
heavily on prevalence studies of HPV DNA in the cervical
epithelium of women undergoing cervical sampling (Woodman
et al, 2001; Kitchener et al, 2006) and usually relates to female
subjects known to be sexually active. These studies indicate the
prevalence of current infection, as most HPV infections are
transient and become DNA negative within 2 years (Moscicki et al,
2006). In individuals who mount a detectable humoral immune
response, HPV type-specific serum antibodies are an indicator of
past exposure. Testing of blood samples also offers the opportunity
to survey different populations.
Enzyme-linked immunosorbent assays (ELISAs) utilising virus-
like particles have been used successfully for seroprevalence
studies in several countries including the USA (Stone et al, 2002)
and Sweden (af Geijersstam et al, 1999). We report on the first
population-based study of HPV 6, 11, 16 and 18 seroprevalence in
England, in 10- to 29-year-old female subjects – the likely target
age range for vaccination, but an age range in which little is known
about infection rates.
MATERIALS AND METHODS
Serum specimens were obtained from the Health Protection
Agency Sero-Epidemiology Unit collection, consisting of unlinked
residual sera submitted to laboratories in England for routine
microbiological or biochemical investigations. Sera from immuno-
compromised individuals and repeat sera from the same
individuals were excluded (Osborne et al, 2000).
Sera were selected from 1483 women aged 10–29 years, chosen
as most important for informing the design of HPV vaccination
programmes in the UK. Sera came from 11 laboratories in England
that collected samples in 2002–2004. About 90 samples were
selected for each single year of age in the range 10–19 years, and
about 60 samples for each of the ages 20–29 years. Samples were
tested for specific neutralising antibodies to HPV 6, 11, 16 and 18
by Merck and Co Inc., using a multiplexed competitive Luminex
s
assay with antibody levels reported in milli-Merck units per
millilitre (mMuml
1) as previously described (Opalka et al, 2003).
Titres were calibrated to ensure comparability with other
published work using the same assay (calibration factors provided
by Mark Esser, personal communication). Sera were assumed to be
seropositive at the cutoffs determined in previous work with this
assay (Dias et al, 2005): 20, 16, 24 and 20mMUml
1 for HPV 6, 11,
16 and 18, respectively.
To calculate the overall seroprevalence, age-specific proportions
were standardised to female population figures from the Office of
National Statistics for England in 2004. Logistic regression models
were used to investigate the risk of seropositivity for each HPV
type, by age, source laboratory location (North or South of
England) and positivity for other HPV types.
RESULTS
Figure 1 shows the seroprevalence of each HPV type by single year
of age in our sample. The age-standardised seroprevalence in
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ywomen aged 10–29 years was 10.7% (95% CI 9.0–12.3) for HPV 6,
2.7% (1.8–3.6) for HPV 11, 11.9% (10.2–13.6) for HPV 16, 4.7%
(3.5–5.8) for HPV 18 and 20.7% (18.6–22.7) for any of the four
assayed types. Also, 7.7% (6.3–9.1) were seropositive for at least
two assayed types: 1.5% (0.9–2.2) for both HPV 6 and 11, and 2.2%
(1.4–3.0) for both HPV 16 and 18. Increasing age was significantly
associated with seropositivity for all HPV types (Po0.01). Being
seropositive for one type was significantly associated with being
seropositive for another (Po0.05), except for the case of HPV 18.
HPV 18 seropositivity was only significantly associated with HPV
16 seropositivity (Po0.01) and not seropositivity for HPV 6 or 11.
There was no consistent, significant risk of HPV seropositivity
associated with sample origin from the North or South of England.
DISCUSSION
Based on our sample, less than 5% of girls under the age of 14
years were seropositive for any HPV type. From age 14 years
onwards, the seroprevalence increased sharply until the early 20s,
and then stabilised or declined. The proportion seropositive varied
by type, being highest for HPV 16 and lowest for HPV 11.
Seropositivity for each of types 6, 11 and 18 was significantly
associated with seropositivity for type 16, which is responsible for
the majority of cervical cancers.
Quantitative titres from the study are not comparable to those
from studies which use different assays, because currently no
international HPV standard reference serum exists, and different
laboratories therefore use ‘in-house’ standard sera making direct
comparisons nonviable (Ferguson et al, 2006). However, the
intended use of the data is to determine the prevalence of past
HPV infection and not to analyse the dynamics of postinfection
antibody levels quantitatively. In this respect, our results are
broadly similar to seroprevalence data in other populations. In the
United States, 6.8 and 24.7% of 12–19 and 20–29 years old female
subjects, respectively, were found by ELISA to have HPV 16
antibodies (Stone et al, 2002). Our results are also consistent with
the onset of sexual activity in the UK, as described by a sexual
behaviour study in 2000 which found that 50% of women reported
sexual debut by age 17 years (Wellings et al, 2001). The results for
HPV 16 and 18 in women of ages eligible for cervical screening
consistently exceeded the proportion of women found to be HPV
DNA positive in a recent study of residual cervical smear samples
(Kitchener et al, 2006), as expected for a persistent marker of
previous infection.
There are a number of issues to consider before using these data
to estimate the incidence of HPV infection. Firstly, seroprevalence
is likely to underestimate the proportion of women who have
had an HPV infection, since other studies have suggested that
only 65–90% of HPV DNA-positive female subjects seroconvert,
with differences in estimates depending on factors including
the testing systems used, how long HPV DNA persists and whether
or not there is progression to disease (Dillner, 1999; Carter
et al, 2000). Seroconversion may coincide with DNA detection,
or may follow by some months; for example, one study found a
delay in seroconversion of 6–12 months after HPV 16 infection,
with type-specific variation seen in the time to seroconversion
(Carter et al, 2000).
The population tested in the survey is not randomly selected but
consists of individuals accessing health care in England and having
blood samples taken for diagnostic or screening investigations.
Previous studies using the same collection have, however, found a
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Figure 1 Seroprevalence of antibodies in female subjects aged 10–29 years using single year age groups for (A) HPV 6, (B) HPV 11, (C) HPV 16,
(D) HPV 18, (E) any assayed HPV type and (F) at least two assayed HPV types. Error bars show exact 95% confidence intervals.
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infections and population vaccine coverage data (Osborne et al,
2000). This suggests that the sample source is broadly representa-
tive of the general population, at least for relatively common
infections. An Australian study in school-aged children has
shown that samples from diagnostic laboratories can give
estimates of immunity to vaccine preventable diseases that are
comparable to random cluster surveys in the general population
(Kelly et al, 2002).
The apparent decline in seroprevalence observed around the age
of 25 years suggests that seroprevalence is not a straightforward
marker of all past HPV infection. Such a marker would be expected
to continue to rise in older women, since DNA studies show
evidence of incident HPV infections in women of all ages, albeit at
a lower rate in older women (Kitchener et al, 2006). There may be
several possible explanations for this. Firstly, the female subjects in
this survey were from different birth cohorts, so changes in
sexual behaviour in the 1970s and 1980s would be reflected in the
results, as has been observed in a similar study in Sweden (af
Geijersstam et al, 1999). The population tested in the survey may
differ by age in terms of how well they represent their age cohort
with respect to HPV infection. Finally, antibody levels are likely to
wane over time, as has been suggested in other studies (Carter
et al, 2000). The use of seroprevalence data such as these to
estimate age-specific infection rates therefore needs to be
investigated further, for example by comparing force of infection
estimates under different assumptions about waning antibody
levels to prevalence data from DNA studies. Further work
involving testing of similar samples from older females (aged
30–49 years) should also inform the pattern of HPV acquisition
throughout life.
Despite these complications, these data offer an additional
viewpoint on the epidemiology of HPV in England, and a rare view
of the age-dependent risk of HPV infection in female subjects who
are not selected for their known sexual activity and who are below
the age eligible for routine cervical screening and in the age range
likely to be targeted with HPV vaccination. They suggest that there
is already a substantial risk of HPV infection in girls in England by
the age of 14 years, which has implications for the age at which
vaccination should be delivered. These data and further analyses
should help to determine the most effective strategies for routine
and catch-up HPV vaccination.
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